The CYP2C19 Enzyme Polymorphism
Author:
- 1 September 2000
- journal article
- review article
- Published by S. Karger AG in Pharmacology
- Vol. 61 (3) , 174-183
Abstract
The genetic test is gradually replacing probe drugs as the primary tool for screening populations for the CYP2C19 polymorphism. A full appreciation for the clinical and toxicological relevance of this genetic variation is presently limited. Further research is needed in several areas. The development and use of 3-D models of the CYP2C19 enzyme to automate and increase the rate at which CYP2C19 substrates are identified could reap great benefits. Meanwhile, clinical research should begin to determine whether the CYP2C19 polymorphism affects therapeutic outcomes and toxicity of drugs in actual patient settings. Combining research efforts in molecular modeling, genetic testing, clinical and epidemiological research will be required if better appreciation of this genetic variation and its importance in the population at large is to emerge.Keywords
This publication has 9 references indexed in Scilit:
- Helicobacter pylori and gastroesophageal reflux disease: to treat or not to treat?Scandinavian Journal of Gastroenterology, 2001
- Intrinsic Efficacy of Proguanil against Falciparum and Vivax Malaria Independent of the Metabolite CycloguanilThe Journal of Infectious Diseases, 1999
- Genetic Polymorphism of Cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese PopulationTherapeutic Drug Monitoring, 1998
- Molecular modelling of human CYP2C subfamily enzymes CYP2C9 and CYP2C19: rationalization of substrate specificity and site-directed mutagenesis experiments in the CYP2C subfamilyXenobiotica, 1998
- Differential stereoselective pharmacokinetics of pantoprazole, a proton pump inhibitor in extensive and poor metabolizers of pantoprazole?a preliminary studyChirality, 1997
- A 2.4-Megabase Physical Map Spanning the CYP2C Gene Cluster on Chromosome 10q24Genomics, 1995
- Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive DyskinesiaJournal of Clinical Psychopharmacology, 1995
- Isolation and Characterization of Human Liver Cytochrome P450 2C19: Correlation between 2C19 and S-Mephenytoin 4′-HydroxylationArchives of Biochemistry and Biophysics, 1993
- Genetic polymorphism of S-mephenytoin hydroxylationPharmacology & Therapeutics, 1989